James Manuso
Director/Board Member at OCUPHIRE PHARMA, INC.
Net worth: 139 522 $ as of 30/04/2024
Profile
James S.
J.
Manuso founded ZyStor Therapeutics, Inc. in 2004 and PrimeTech Partners in 1998, where he worked as General Partner from 1998 to 2002.
Dr. Manuso also founded Galenica Pharmaceuticals, Inc., where he worked as Chairman, President & Chief Executive Officer, Symbiontics, Inc., where he worked as Chairman, and Laurelside LLC, where he worked as Managing Member.
Dr. Manuso also currently works at Talfinium Investments, Inc., as Chairman & Chief Executive Officer from 2014, KineMed, Inc., as Director from 2001, Morphogenesis, Inc., as Director, Ocuphire Pharma, Inc., as Independent Director from 2019, and AAON Coil Products, Inc., as Managing General Partner.
Dr. Manuso also formerly worked at RespireRx Pharmaceuticals, Inc., as Vice Chairman, President & Chief Executive Officer from 2015 to 2018, SuperGen, Inc., as Chairman & Chief Executive Officer in 2011, Astex Pharmaceuticals, Inc., as Chairman & Chief Executive Officer from 2011 to 2013, EACOM Timber Corp., as Chairman, Biotechnology Innovation Organization, as Chairman, Merrion Pharmaceuticals Plc, as Chairman, Quark Pharmaceuticals, Inc., as Chairman, Eurogen Ltd, as Chairman, Supratek Pharma, Inc., as Chairman, Novelos Therapeutics, Inc., as Chairman from 2011 to 2014, Montigen Pharmaceuticals, Inc., as Chairman, Leukemia & Lymphoma Society Greater San Francisco Bay Area, as Chairman, Trustee & Vice President, The Equitable Cos., Inc., as VP, Director-Health Care Planning & Development, OcuSub, Inc., as Director from 2019 to 2020, The Channel Group, as Managing General Partner, and Manuso Alexander & Associates, Inc., as President.
Dr. Manuso received his doctorate degree from The New School, undergraduate degree from New York University, and Masters Business Admin degree from Columbia Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
OCUPHIRE PHARMA, INC.
0.37% | 01/01/2024 | 90,894 ( 0.37% ) | 139 522 $ | 30/04/2024 |
James Manuso active positions
| Companies | Position | Start |
|---|---|---|
| KINEMED INC | Director/Board Member | 01/03/2001 |
| OCUPHIRE PHARMA, INC. | Director/Board Member | 01/01/2019 |
| Laurelside LLC | Founder | - |
| Talfinium Investments, Inc. | Chief Executive Officer | 01/01/2014 |
AAON Coil Products, Inc.
 AAON Coil Products, Inc. Industrial MachineryProducer Manufacturing Part of AAON, Inc., AAON Coil Products, Inc. manufactures and markets air-conditioning and heating equipment. The company is based in Longview, TX. Gary D. Fields has been the CEO of the company since 2018. | Corporate Officer/Principal | - |
Morphogenesis, Inc.
 Morphogenesis, Inc. BiotechnologyHealth Technology Morphogenesis, Inc. develops targeted immunotherapies research. It focuses on the development of cell and gene therapies for the treatment of cancer. The company was founded by Patricia Lawman and Michael Lawman in 1990 and is headquartered in Tampa, FL. | Director/Board Member | - |
Former positions of James Manuso
| Companies | Position | End |
|---|---|---|
OcuSub, Inc.
 OcuSub, Inc. BiotechnologyHealth Technology OcuSub, Inc. engages biotechnology services. It specializes in eye disorder treatment. The company was founded by Mina Patel Sooch, Alan R. Meyer, and William H. Pitlick in 2018 and is headquartered in Farmington Hills, MI. | Director/Board Member | 01/11/2020 |
| RESPIRERX PHARMACEUTICALS INC. | Chief Executive Officer | 30/09/2018 |
Novelos Therapeutics, Inc.
 Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Chairman | 12/02/2014 |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of James Manuso
| The New School | Doctorate Degree |
| New York University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| RESPIRERX PHARMACEUTICALS INC. | Health Technology |
| OCUPHIRE PHARMA, INC. | Health Technology |
| Private companies | 24 |
|---|---|
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
KineMed, Inc.
 KineMed, Inc. Miscellaneous Commercial ServicesCommercial Services KineMed, Inc. develops and commercializes biomarker platform technology. It provides dynamic proteomics platform, a functionally interpretable systems biology platform. The company was founded by David M. Fineman and Marc K. Hellerstein in February 2001 and is headquartered in Emeryville, CA. | Commercial Services |
EACOM Timber Corp.
 EACOM Timber Corp. Forest ProductsNon-Energy Minerals EACOM Timber Corp. engages in the manufacture and distribution of lumber and wood-based products, and the management of forest resources. It offers stud grade lumber, dimension lumber, machine-stress rated lumber, specialty lumber and engineered woods. The company was founded by Hassan Salari on April 2, 1980 and is headquartered in Montreal, Canada. | Non-Energy Minerals |
Morphogenesis, Inc.
Morphogenesis, Inc. BiotechnologyHealth Technology Morphogenesis, Inc. develops targeted immunotherapies research. It focuses on the development of cell and gene therapies for the treatment of cancer. The company was founded by Patricia Lawman and Michael Lawman in 1990 and is headquartered in Tampa, FL. | Health Technology |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Merrion Pharmaceuticals Plc
 Merrion Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Merrion Pharmaceuticals Plc engages in the development of oral forms of drugs which have suboptimal absorption. It also invests in companies focusing in the healthcare sector. The company was founded by Michael Mary Donnelly in December 2003 and is headquartered in Dublin, Ireland. | Health Technology |
| The Equitable Cos., Inc. | Finance |
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
Eurogen Ltd
 Eurogen Ltd Packaged SoftwareTechnology Services Part of Servoca Plc, Eurogen Ltd designs software. The company is based in Pulborough, UK. Eurogen was acquired by Multi Group Plc on December 11, 2000 for $0.40 million. | Technology Services |
Galenica Pharmaceuticals, Inc.
 Galenica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galenica Pharmaceuticals, Inc. develops vaccines. The company was founded by Jacques Marcotte and James S. Manuso and is headquartered in Birmingham, AL. | Health Technology |
Supratek Pharma, Inc.
 Supratek Pharma, Inc. Pharmaceuticals: MajorHealth Technology Supratek Pharma, Inc. develops drugs and related oncology therapeutic products. It offers injectable chemotherapeutic that enhances or enables an approved anticancer drug. The firm’s products include SP1014C - a novel cabazitaxel against drug resistant prostate cancer, SP1030C - novel bendamustine against chronic lymphocytic leukemia and non-Hodgkin’s lymphoma and SP1049C - a novel injectable anthracycline platform drug against chemoresistant cancers. The company was founded by Valery Alakhov in 1994 and is headquartered in Pointe-Claire, Canada. | Health Technology |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Health Technology |
ZyStor Therapeutics, Inc.
 ZyStor Therapeutics, Inc. Medical SpecialtiesHealth Technology ZyStor Therapeutics, Inc. develops innovative therapeutics. It offers enzyme replacement therapies for the treatment of lysosomal storage diseases. The company was founded by Brian L. Clevinger, James S. Manuso and Allan R. Goldberg and is headquartered in Milwaukee, WI. | Health Technology |
Montigen Pharmaceuticals, Inc.
 Montigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Montigen Pharmaceuticals, Inc. developed pharmaceutical products used for the treatment of cancer. Its products addressed oncology drug market with demonstrated preclinical activity in various solid tumor types, including pancreatic, colorectal, breast, prostate, and ovarian cancers. The company was founded in 2003 and was headquartered in Salt Lake City, UT. | Health Technology |
The Channel Group
 The Channel Group Investment ManagersFinance The Channel Group is a venture management and corporate advisory business headquartered in Harrison, New York. | Finance |
AAON Coil Products, Inc.
AAON Coil Products, Inc. Industrial MachineryProducer Manufacturing Part of AAON, Inc., AAON Coil Products, Inc. manufactures and markets air-conditioning and heating equipment. The company is based in Longview, TX. Gary D. Fields has been the CEO of the company since 2018. | Producer Manufacturing |
| PrimeTech Partners | |
| Manuso Alexander & Associates, Inc. | |
| Symbiontics, Inc. | |
| Leukemia & Lymphoma Society Greater San Francisco Bay Area | |
Astex Pharmaceuticals, Inc.
 Astex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded on May 28, 1997 and is headquartered in Pleasanton, CA. | Health Technology |
| Talfinium Investments, Inc. | |
OcuSub, Inc.
OcuSub, Inc. BiotechnologyHealth Technology OcuSub, Inc. engages biotechnology services. It specializes in eye disorder treatment. The company was founded by Mina Patel Sooch, Alan R. Meyer, and William H. Pitlick in 2018 and is headquartered in Farmington Hills, MI. | Health Technology |
| Laurelside LLC |
- Stock Market
- Insiders
- James Manuso
